Vayamed und telaleaf Logo

Vayamed and telemedicine pioneer Telaleaf launch exclusive partnership

Share this post

German medical cannabis specialist Vayamed and the telemedicine platform Telaleaf agreed on an exclusive partnership to strengthen telemedicine in cannabis therapy in Germany. The focus will be on therapy quality, patient centered pricing, individual therapy plans, and equitable therapy access. Telaleaf is a pioneer in cannabis-based telemedicine from Canada established in 2020 and will now launch its services in the German healthcare system.

Telaleaf, a telemedicine company transforming the access and delivery of medical cannabis care to patients, and Berlin-based medical cannabis brand Vayamed are pleased to announce a strategic partnership to strengthening the quality of telemedicine services in cannabis therapy in Germany through premium quality virtual care and to improve access, in line with Vayamed’s brand vision: “Medicine from Nature. Customized for Patients”. Vayamed and Telaleaf are driven by the vision that telemedicine will continue to move healthcare delivery from clinic to home, and will become the standard in cannabis-based medicine. Doctor visits to consult about Vayamed products and treatment options are planned as well as further programs in the field of talent support and further training at leading medical faculties nationwide. 

“The importance of telemedicine in the German healthcare system will continue to grow. It offers many benefits for doctors, patients and the healthcare system, for example better access and treatment quality, qualified trainings, and improved health insurance reimbursement levels through special training offers for doctors. Together with Telaleaf, we want to improve therapies with medical cannabis in Germany through the utilization of telemedicine”, said Thimo V. Schmitt-Lord, Director New Markets & Innovation at Vayamed.

“In order to fully realize the vision of cannabis-based medicine as the advanced, alternative medicinal modality it has proven to be, Telaleaf has entirely reimagined the cannabis healthcare delivery model such that all necessary medical services, tools and resources come together for patients and doctors under one unified field. Our joint mission with Vayamed is to drive better health outcomes for patients with personalized virtual care that is sustained by expert-led medicinal cannabis training and education,” said Telaleaf CEO Gavin Treanor.

Telaleaf collaborates with leading experts such as Prof. Kirsten Müller-Vahl, M.D., and Franjo Grothenhermen, M.D., and the medical cannabis training for participating doctors is provided at the highest educational level in cooperation with Dresden International University.

About Vayamed 
Medical cannabis specialist Vayamed, a brand of Berlin-based health and life science company Sanity Group, specializes in the development and distribution of innovative cannabinoid-based medicinal products for the European market and, as a reliable provider, is committed to making medical cannabis accessible to doctors, pharmacists and patients. 

About Telaleaf
Telaleaf is a telemedicine company transforming the delivery of cannabis care by connecting patients to expert doctors, trained in cannabis-based medicine, who conduct virtual medical visits and provide personalized treatment plans. Our aim is to improve patient outcomes, by improving the patient experience with high quality treatment, ease of access and expert-led training to doctors, for the most advanced virtual care in cannabis medicine.

Share this post

Latest news

April 16, 2026
Sanity Group
Organigram Global and Sanity Group Announce Successful Closing of Acquisition
April 1, 2026
Sanity Group
Evaluation Report on Second Anniversary of German Cannabis Act: Sanity Group Calls for Evidence-Based Regulation
March 23, 2026
Sanity Group
Sanity Group and Curaleaf Laboratories Announce Partnership to Advance Medical Cannabis Innovation in the UK
April 12, 2023
Sanity Group
Cannabis legalization in Germany – Statement on the revised cornerstone paper
January 12, 2023
Sanity Group
Endosane Pharmaceuticals agrees to Licence Agreement with PreveCeutical Medical thereby Securing Exclusive Rights to Innovative Technology
Get in touch

For general enquiries, please email info@sanitygroup.com. For specific topics you can reach the right team in the sidebar. You’ll also find links for cultivation collaborations and pilot studies in our footer.

Interested in a career at Sanity Group?

Visit careers page